Trials / Active Not Recruiting
Active Not RecruitingNCT04231851
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
Phase II Study of the Combination of CPX-351 and Glasdegib in Previously Untreated Patients With Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- University of California, Irvine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2 single-arm, open-label clinical trial determining efficacy of CPX-351 in combination with Glasdegib in subjects with Acute Myelogenous Leukemia with myelodysplastic syndrome related changes or therapy-related acute myeloid leukemia.
Conditions
- Acute Myelogenous Leukemia (AML) Due to Therapy
- Acute Myeloid Leukemia With Myelodysplasia-Related Changes
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glasdegib | Given PO |
| DRUG | CPX-351 | Given IV |
Timeline
- Start date
- 2020-02-19
- Primary completion
- 2024-06-30
- Completion
- 2027-06-30
- First posted
- 2020-01-18
- Last updated
- 2026-03-06
- Results posted
- 2026-03-06
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04231851. Inclusion in this directory is not an endorsement.